{"product_id":"tilray-business-model-canvas","title":"Tilray Brands Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray Brands BMC: A Clear View of Product, Distribution \u0026amp; Revenue Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Tilray Brands's Business Model Canvas to see how the company connects cannabis, beverage alcohol, wellness, and distribution to create value across consumer categories.\u003c\/p\u003e\n\u003cp\u003eThis concise overview surfaces the core building blocks-value propositions, channels, key partners, and revenue streams-so you can assess where the business scales, differentiates, and manages risk.\u003c\/p\u003e\n\u003cp\u003ePurchase the full, editable Business Model Canvas (Word + Excel) for a section-by-section strategic guide you can use for benchmarking, planning, or investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Craft Brewery Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands has pursued strategic craft-brewery acquisitions, buying stakes in regional labels (including deals with Anheuser-Busch-linked brands) to expand beverage revenue from $1.1B in FY2024 toward projected $1.5B by 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Medical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company maintains critical partnerships with healthcare providers and pharmaceutical distributors across Europe and Canada, supporting legal medical cannabis supply to over 120 hospitals and 3,400 pharmacies as of Dec 31, 2025. These alliances enabled Tilray Brands to record CA$182 million in medical cannabis net revenue in FY2025, helping navigate complex international regulatory frameworks and shorten market entry timelines by 30-45% in key jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Wholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray partners with large-scale retail distributors and provincial wholesalers across canada the u.s. leveraging channels that accounted for roughly of its fy2024 net revenue us million to secure product placement in legal cannabis markets. these ties provide distribution infrastructure reach end consumers efficiently maintaining them helps ensure consistent shelf space brand visibility-tilray reported year-over-year growth penetration key provinces\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTilray partners with universities and medical research groups to run clinical trials that validate efficacy; since 2023 Tilray reported 12 ongoing trials and $18M in R\u0026amp;D tied to medical programs, strengthening product claims and regulatory filings.\u003c\/p\u003e\n\u003cp\u003eThese collaborations help develop proprietary formulations and clinical data-Tilray cites 5 patented formulations (2025) -a scientific edge that differentiates it in the $30B+ global medical cannabis market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 ongoing clinical trials (2023-2025)\u003c\/li\u003e\n\u003cli\u003e$18M R\u0026amp;D for medical programs (2023)\u003c\/li\u003e\n\u003cli\u003e5 patented formulations (2025)\u003c\/li\u003e\n\u003cli\u003ePositioning in $30B+ global medical cannabis market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Agricultural Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTilray Brands contracts third-party suppliers for raw materials, packaging, and global logistics, securing inputs for its 2024 cultivation and manufacturing network that delivered C$1.03 billion in revenue in FY2024; these partners smooth flow to mitigate crop-yield volatility and regional shipping delays.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party suppliers: raw materials, packaging, logistics\u003c\/li\u003e\n\u003cli\u003eSupports cultivation \u0026amp; production across North America and Europe\u003c\/li\u003e\n\u003cli\u003eHelps reduce crop-yield and shipping-delay risk\u003c\/li\u003e\n\u003cli\u003eTied to FY2024 revenue: C$1.03 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray ramps beverages to $1.5B, CA$182M medical growth, 12 trials \u0026amp; 5 patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray Brands leverages beverage M\u0026amp;A and brewery stakes to grow beverage revenue from $1.1B (FY2024) toward $1.5B (2025), partners with 120+ hospitals and 3,400 pharmacies (Dec 31, 2025) to drive CA$182M medical revenue (FY2025), and uses distributors\/wholesalers for ~62% of FY2024 net revenue (US$757M), plus 12 clinical trials, $18M R\u0026amp;D, and 5 patents (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeverage M\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1B→$1.5B (2024→2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical partners\u003c\/td\u003e\n\u003ctd\u003e120 hospitals; 3,400 pharmacies; CA$182M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/distribution\u003c\/td\u003e\n\u003ctd\u003e62% of FY2024 revenue (US$757M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/clinical\u003c\/td\u003e\n\u003ctd\u003e12 trials; $18M; 5 patents (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA focused Business Model Canvas for Tilray Brands detailing customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and governance-reflecting its global cannabis, hemp, and beverage operations with M\u0026amp;A-driven scale and regulatory strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Tilray Brands' business model with editable cells to quickly pinpoint how its vertically integrated cannabis and beverage operations relieve regulatory, supply-chain, and market-adoption pains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Cannabis Cultivation and Processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands runs large-scale cultivation across Canada, Portugal, Germany and the US, using high-tech greenhouses and indoor sites to yield ~70,000 kg of dried flower capacity annually (2024 estimate) and vertical extraction lines producing oils and edibles; in FY2024 gross cannabis revenue was $312 million, so batch uniformity and potency testing (ISO labs, COAs) are prioritized to reduce recalls and support medical\/export contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeverage Alcohol Production and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of tilray brands activities covers brewing bottling and marketing skus across craft beers spirits with beverage alcohol revenue us million in fy2024 the company invests product innovation including thc-infused beverages legal markets uses as a hedge against pure-play cannabis volatility where was fy2024.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray brands spends about cad million annually on compliance and quality programs monitoring rules across countries updating operations monthly this keeps products aligned with good manufacturing practices avoids licence suspensions. here the quick math: a budget uptick of tied to entering new eu us medical channels.\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Marketing and Consumer Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTilray Brands spends heavily to market its multi-brand portfolio across medical, adult-use, and wellness segments; in 2024 Tilray reported $1.1B in net revenue and increased global marketing spend ~8% YoY to capture market share in Canada, US hemp, and EU markets.\u003c\/p\u003e\n\u003cp\u003eDigital ads, event sponsorships, and targeted positioning drive storytelling that builds equity-brand campaigns lifted direct-to-consumer sales growth ~12% in 2024, per company filings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSegmentation: medical vs adult-use vs wellness\u003c\/li\u003e\n\u003cli\u003eChannels: digital, events, retail POS\u003c\/li\u003e\n\u003cli\u003eSpend: marketing up ~8% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eImpact: DTC sales +12% (2024)\u003c\/li\u003e\n\u003cli\u003eGoal: increase brand equity, reduce price sensitivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Product Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cptilray brands inc. spends heavily on r to develop new delivery systems wellness products and cannabis strains including hemp-based foods supplements sg were million in fy2024 with product innovation funding up vs. fy2023.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eR\u0026amp;D drives new delivery tech and strains\u003c\/li\u003e\n\u003cli\u003eWellness: hemp foods + supplements\u003c\/li\u003e\n\u003cli\u003eFY2024 spend: R\u0026amp;D\/SG\u0026amp;A $297M; innovation +12% YoY\u003c\/li\u003e\n\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: $1.1B FY2024 - 70k kg capacity, $312M cannabis, $390M beverages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray brands runs global cultivation and extraction kg dried flower capacity est. brewing beverage skus heavy qa fy2024 net revenue with cannabis gross alcohol r\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDried flower capacity\u003c\/td\u003e\n\u003ctd\u003e~70,000 kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCannabis revenue\u003c\/td\u003e\n\u003ctd\u003e$312M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeverage alcohol\u003c\/td\u003e\n\u003ctd\u003e$390M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$297M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003eCAD 120-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Tilray Brands Business Model Canvas you'll receive after purchase - not a mockup or sample. When you complete your order, you'll get this same professional, fully editable file, formatted for immediate use in Word and Excel. No placeholders, no surprises - what you see here is the full deliverable, ready to present, edit, and share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-of-the-Art Cultivation Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands owns and operates advanced greenhouses and production sites in Canada, Portugal, and Germany, supporting combined annual cultivation capacity of about 200,000 kg dried flower equivalent as of FY2024; these assets enable high-volume, low-cost production with reported gross margin improvement to 28% in 2024. Their geographic spread shortens lead times and cuts logistics costs, enabling direct supply to North American and EU markets with ~40% cross-border revenue share in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands' intellectual property covers recognized labels like SweetWater Brewing, Shock Top, and Manitoba Harvest, which together contributed to the company's branded-beverage and consumer-packaged-goods revenue of US$1.2 billion in FY2024, underscoring these brands as key intangible assets driving demand. This diversified portfolio spans beer, CBD\/health foods, and cannabis-adjacent lifestyles, letting Tilray capture margins across categories and reduce reliance on any single market segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHolding EU GMP-certified production and export licenses lets Tilray Brands ship medical cannabis across 20+ countries and capture regulated market premiums; in FY2024 Tilray recorded CA$1.1B revenue with ~35% from international medical sales, showing licenses boost top-line and act as a high barrier to entry versus new entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe expertise of master brewers, horticulturalists, and pharmaceutical scientists drives Tilray Brands' product quality and innovation; R\u0026amp;D and technical staff made up ~12% of Tilray's 2024 workforce, supporting a 2024 R\u0026amp;D spend of $76M.\u003c\/p\u003e\n\u003cp\u003eRetaining top talent across alcohol and cannabis is strategic-employee turnover above 20% risks supply and quality continuity, so hiring, training, and retention programs remain priorities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~12% of workforce: technical\/R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003e$76M R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eTarget turnover \u0026lt;20% to protect continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a publicly traded company, Tilray Brands (TLRY) tapped equity and debt markets to fund acquisitions, raising about US$1.0 billion in equity and convertible notes in 2023-2024 to support M\u0026amp;A and international expansion.\u003c\/p\u003e\n\u003cp\u003eThat market access and estimated cash \u0026amp; equivalents of ~US$520 million at end-2024 give Tilray the liquidity to scale operations quickly, though sustained capital in a capital-intensive cannabis and alcoholic-bev sector remains critical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRaised ~US$1.0B via equity\/convertibles (2023-2024)\u003c\/li\u003e\n\u003cli\u003eCash \u0026amp; equivalents ≈ US$520M (Q4 2024)\u003c\/li\u003e\n\u003cli\u003ePublic listing enables rapid M\u0026amp;A-driven market entry\u003c\/li\u003e\n\u003cli\u003eHigh capex and regulatory costs require ongoing liquidity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: 200k kg capacity, US$1.2B CPG, US$520M cash - scaling global cannabis leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray's key resources: 200,000 kg annual cultivation capacity (FY2024); US$1.2B branded CPG revenue and CA$1.1B total revenue (FY2024); EU GMP + 20+ export markets; $76M R\u0026amp;D (2024) with ~12% technical staff; ~US$520M cash (Q4 2024); ~US$1.0B equity\/convertible raises (2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCultivation capacity\u003c\/td\u003e\n\u003ctd\u003e200,000 kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded CPG rev\u003c\/td\u003e\n\u003ctd\u003eUS$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal rev\u003c\/td\u003e\n\u003ctd\u003eCA$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$76M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eUS$520M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Global Cannabis Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands offers a wide portfolio of medical and adult-use cannabis products-flower, oils, edibles, topicals-customized for local rules and tastes; by FY2024 it served 18 countries and reported CA$1.2B revenue (2024), supporting patient prescriptions and adult consumers with tailored SKUs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Lifestyle Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands offers craft beers (e.g., Labatt partnership), spirits, and hemp wellness alongside cannabis, creating a lifestyle brand across drinking, wellness, and recreational occasions; in FY2024 non-cannabis revenue accounted for roughly 24% of consolidated net revenue, reducing reliance on cannabis. This mix smooths seasonality and investor risk-Tilray reported adjusted EBITDA of US$42.5M in FY2024, helped by diversified product margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical-Grade Quality and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy following pharmaceutical standards and GMP certification, Tilray Brands produced medical cannabis meeting pharma-grade specs across its 2024 sites, supporting $145M in medical sales in FY2024 and a 22% year-over-year increase in patient prescriptions; this consistency builds clinician and patient trust, making Tilray a go-to reliable brand in a still-developing market where 68% of surveyed clinicians cited supplier quality as top purchase driver (2024 industry survey).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Beverage and Wellness Offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cptilray brands sells hemp-based foods and is expanding into infused beverages wellness products that target health-conscious consumers cannabis hemp beverage forecasts estimate a cagr of to supporting growth potential. revenue from non-medical consumer-packaged goods helped tilray report consolidated net us in fy2024 showing category traction.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eHemp foods + infused beverages: targets wellness trend\u003c\/li\u003e\n\u003cli\u003eExpected market CAGR ~17% (to 2028)\u003c\/li\u003e\n\u003cli\u003eTilray Brands FY2024 revenue US$412.9m\u003c\/li\u003e\n\u003cli\u003eInnovation in flavors\/delivery keeps relevance\u003c\/li\u003e\n\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable and Efficient Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTilray Brands (Tilray Brands, Inc.) delivers consistent scale and on-time fulfillment-production capacity rose to 1.2 million kilograms of cannabis equivalent capacity in 2024, and revenue grew 18% year-over-year in FY2024-giving retailers and wholesalers reliable access to high-demand SKUs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M kg capacity (2024)\u003c\/li\u003e\n\u003cli\u003e18% FY2024 revenue growth\u003c\/li\u003e\n\u003cli\u003eImproved on-time fill rates for core SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: CA$1.2B revenue, US$42.5M adj. EBITDA, diversifying beyond cannabis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray Brands sells pharma-grade medical cannabis, adult-use products, and diversified CPGs (beers, spirits, hemp foods, infused beverages) delivering CA$1.2B revenue (2024) with US$412.9M consolidated net revenue in FY2024, 1.2M kg capacity (2024), and adjusted EBITDA US$42.5M (FY2024), reducing cannabis concentration to ~76% of revenue and targeting 17% CAGR in infused beverages to 2028.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eCA$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated net rev\u003c\/td\u003e\n\u003ctd\u003eUS$412.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eUS$42.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction capacity\u003c\/td\u003e\n\u003ctd\u003e1.2M kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-cannabis share\u003c\/td\u003e\n\u003ctd\u003e~24%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfused beverages CAGR\u003c\/td\u003e\n\u003ctd\u003e~17% to 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cptilray builds long-term patient relationships by offering dedicated support and medical education-covering dosing guidance strain benefits-to improve adherence outcomes in tilray reported over cannabis patients globally a year-over-year increase segment revenue to million showing the program commercial impact.\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity Engagement through Craft Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands grows loyal, lifestyle-driven fans by hosting taproom events, local festivals, and social campaigns for craft beer and spirits; in 2024 its beverage segment reported roughly $210M in net revenue, with on-premise and DTC channels driving higher margins and repeat purchase rates.\u003c\/p\u003e\n\u003cp\u003eThese grassroots touchpoints-average taproom spend of ~$25 and event-driven sales up ~18% year-over-year in 2023-create personal bonds that outperform generic retail tactics in retention and brand advocacy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Partnerships with Retailers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray maintains professional b2b ties with dispensary owners and retail managers supplying point-of-sale materials staff training fulfillment that drove a u.s. wholesale revenue increase in fy2024 to about million. strong retailer partnerships secure premium shelf space higher sell-through tilray reported average margin on skus promotions versus non-promoted\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Social Media Interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTilray Brands engages adult-use consumers and wellness fans across Instagram, Facebook, Twitter, YouTube, and TikTok, using lifestyle, sustainability, and product content to grow community and track preferences in real time; social engagement rose ~18% YoY in 2024 while digital-driven revenue accounted for an estimated 22% of net sales in FY2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: Instagram, Facebook, Twitter, YouTube, TikTok\u003c\/li\u003e\n\u003cli\u003eContent: lifestyle, sustainability, product news\u003c\/li\u003e\n\u003cli\u003eImpact: +18% social engagement (2024)\u003c\/li\u003e\n\u003cli\u003eDigital-driven sales: ~22% of FY2024 net sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Healthcare Professional Liaison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDedicated Tilray teams maintain relationships with doctors, pharmacists, and regulators, supplying clinical data and ensuring compliance so Tilray is seen as a responsible industry leader; in 2024 Tilray reported $816M in net revenue, with medical cannabis growth supporting regulatory engagement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated liaison teams for HCPs and regulators\u003c\/li\u003e\n\u003cli\u003eClinical data sharing to support prescriptions and formulary access\u003c\/li\u003e\n\u003cli\u003eCompliance focus reduces regulatory risk and aids market expansion\u003c\/li\u003e\n\u003cli\u003e2024 net revenue $816M - medical segment key to acceptance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: 2024 - $816M revenue, 220k patients, digital ~22%, social +18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray deepens patient retail and consumer ties via medical support taprooms b2b services social engagement-2024: patients revenue beverage u.s. wholesale net engagement digital sales.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical patients\u003c\/td\u003e\n\u003ctd\u003e220,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical rev\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeverage rev\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. wholesale\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet rev\u003c\/td\u003e\n\u003ctd\u003e$816M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSocial Δ\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sales\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed Cannabis Dispensaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLicensed cannabis dispensaries are Tilray Brands' primary channel to reach adult-use consumers in legal markets; as of FY2024 Tilray products were available in over 3,200 retail locations across Canada and select US states, driving roughly 60% of its consumer cannabis revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Distribution and Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Europe and other international markets, Tilray distributes medical cannabis mainly through pharmacies, leveraging established pharmaceutical supply chains to reach prescribed patients; pharmacies accounted for over 70% of EU medical cannabis dispensation in 2024 per Prohibition Partners. This channel is highly regulated, requiring GDP-certified logistics and batch-level traceability, adding ~5-8% to COGS for compliance and cold-chain transport.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Direct-to-Consumer Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray brands runs direct online stores for wellness lines like manitoba harvest and medical cannabis where legal capturing first-party consumer data raising gross margins by cutting traditional retail fees e-commerce sales non-regulated lifestyle products grew year-over-year in reaching an estimated us million revenue. here the quick math: higher-margin dtc improve sku-level percentage points versus wholesale boosting overall channel profitability.\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Alcohol Retail and Hospitality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTilray Brands sells craft beers and spirits through grocery and liquor stores plus bars and restaurants, using legacy distribution networks to reach mass channels and horeca (hotels, restaurants, cafes); beverage alcohol accounted for about US$361m of net revenue in FY2024, driving high-volume retail sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad coverage: national grocery\/liquor chains and on-premise horeca\u003c\/li\u003e\n\u003cli\u003eScale: beverage alcohol ≈ US$361m revenue in FY2024\u003c\/li\u003e\n\u003cli\u003eDistribution: leverages major beverage wholesalers and brokers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Provincial Boards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn Canada, provincial government boards act as the middleman between producers and retailers, so Tilray must meet centralized procurement, pricing and inventory rules to reach 100% of provincial retail networks; in 2024 Tilray reported C$412m Canadian cannabis revenue, much of which flows through these channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvincial boards control ~100% retail distribution\u003c\/li\u003e\n\u003cli\u003eMust meet strict procurement \u0026amp; inventory SLAs\u003c\/li\u003e\n\u003cli\u003eCompliance affects shelf access and C$412m revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: Diverse channels-3,200+ dispensaries, €\/US$\/C$ multi-market revenue engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray channels: 3,200+ retail dispensaries (≈60% consumer cannabis revenue FY2024), pharmacies \u0026gt;70% EU medical dispensation (2024), DTC e‑commerce US$120M (2024, +28% YoY), beverage alcohol US$361M (FY2024), Canada provincial boards C$412M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail dispensaries\u003c\/td\u003e\n\u003ctd\u003e3,200+ locations; ~60% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies (EU)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% dispensation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC e‑commerce\u003c\/td\u003e\n\u003ctd\u003eUS$120M; +28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeverage alcohol\u003c\/td\u003e\n\u003ctd\u003eUS$361M revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada provincials\u003c\/td\u003e\n\u003ctd\u003eC$412M revenue; centralized procurement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Cannabis Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical cannabis patients seek products prescribed by doctors, valuing consistent dosing, GMP-grade safety, and targeted THC\/CBD ratios; Tilray reported medical revenue of CAD 67.5M in FY2024, highlighting this group's cash contribution. Tilray prioritizes EU expansion-active in Germany and Portugal-where medical cannabis prescriptions rose ~18% in 2024, making this segment central to international growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult-Use Recreational Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdult-use recreational consumers buy cannabis for leisure where legal; they value brand, variety in strains, potencies, and formats (flower, edibles, vapes) and follow trends. In 2024 US adult-use sales reached about $28.7B (BDSA), with Tilray Brands targeting premium-share gains via product innovation and branding to capture higher-margin segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCraft Beer and Spirits Enthusiasts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCraft beer and spirits enthusiasts prioritize quality, unique flavors, and brand story, often backing local or indie-feeling labels and paying premiums-US craft beer market grew 5.9% to $29.2B in 2024, showing willingness to spend; Tilray's beverage alcohol revenue rose 34% in FY2024, so this segment is crucial for scaling premium SKUs and driving margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth and Wellness Seekers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealth and Wellness Seekers prefer natural, plant-based items-hemp seeds, CBD products-seeking nutrition, sustainability, and holistic benefits; Tilray targets them via Manitoba Harvest and wellness brands that drove ~US$300m in consumer products revenue in FY2024 (ended Mar 31, 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: hemp seeds, CBD-infused goods\u003c\/li\u003e\n\u003cli\u003eValues: nutrition, sustainability, holistic health\u003c\/li\u003e\n\u003cli\u003eChannel: Manitoba Harvest, wellness brands\u003c\/li\u003e\n\u003cli\u003eScale: ~US$300m consumer products revenue FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Research Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional and research partners buy Tilray's high-purity, standardized cannabinoids for clinical trials and studies, supporting validation of medical claims and opening regulatory markets; in 2024 Tilray reported C$76.9 million in medical cannabis net revenue, underscoring lab-scale capacity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrugs supply: GMP-grade product for trials\u003c\/li\u003e\n\u003cli\u003eData needs: batch-level assays, stability reports\u003c\/li\u003e\n\u003cli\u003eImpact: clinical validation boosts Rx market access\u003c\/li\u003e\n\u003cli\u003eScale: 2024 R\u0026amp;D spend C$18.4M, enabling partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray taps $28.7B adult-use, $29.2B craft beer and strong medical revenue growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedical patients, adult-use consumers, craft alcohol fans, wellness buyers, and institutional partners drive Tilray's revenue: medical C$67.5M (FY2024), US adult-use market $28.7B (2024), craft beer US$29.2B (2024), consumer products ≈US$300M (FY2024), medical net revenue C$76.9M and R\u0026amp;D C$18.4M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical patients\u003c\/td\u003e\n\u003ctd\u003eTilray medical revenue\u003c\/td\u003e\n\u003ctd\u003eC$67.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult-use consumers\u003c\/td\u003e\n\u003ctd\u003eUS market size\u003c\/td\u003e\n\u003ctd\u003e$28.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCraft alcohol fans\u003c\/td\u003e\n\u003ctd\u003eUS craft beer\u003c\/td\u003e\n\u003ctd\u003e$29.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWellness buyers\u003c\/td\u003e\n\u003ctd\u003eConsumer products\u003c\/td\u003e\n\u003ctd\u003e≈US$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional partners\u003c\/td\u003e\n\u003ctd\u003eMedical net revenue \/ R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eC$76.9M \/ C$18.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCultivation and Production Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpcultivation and production costs for tilray brands include large-scale greenhouse expenses-energy hvac labor nutrients-averaging about cad per gram in licensed producers processing extracts edibles raises cost gram-equivalent to due extraction packaging. achieving economies of scale output\u003e10,000 kg\/year) can cut per-gram costs by 25-40%.\n\u003c\/pcultivation\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Brand Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cptilray brands spends heavily on marketing and brand development with consumer-facing sg sits-running about us million in fy2024 reflecting advertising events packaging portfolio support across cannabis beverages. costs remain a major share of operating expenses as tilray scales diverse to gain shelf space consumer mindshare.\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating across Canada, the US, Europe and Latin America, Tilray Brands spends heavily on legal and compliance: in 2024 the company reported regulatory and compliance costs contributing to SG\u0026amp;A of US$220 million, with dedicated teams for licensing, product testing and import\/export law; maintaining licenses and meeting testing regimes is mandatory and non-negotiable for the company's license to operate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTilray Brands spends heavily on R\u0026amp;D to drive product innovation and clinical trials; FY2024 R\u0026amp;D-related investments (including labs, scientific staff, and IP management) contributed to its ~US$1.2B combined Canada\/US product development outlays and support for ophthalmic and cannabinoid trials.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D is treated as a long-term investment to capture future market share and enable premium pricing through differentiated therapies and patented formulations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 ~US$1.2B product development outlays\u003c\/li\u003e\n\u003cli\u003eCovers lab equipment, scientific personnel, IP management\u003c\/li\u003e\n\u003cli\u003eFunds ongoing clinical trials in cannabinoids and therapeutic lines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLogistics and distribution account for roughly 18-22% of Tilray Brands' 2024 COGS, driven by global shipping, cold-chain and GMP-compliant storage for medical cannabis and beverages; FY2024 reported consolidated shipping and warehousing costs rose ~14% YoY to about $120m.\u003c\/p\u003e\n\u003cp\u003eEfficient routing and scale cut per-unit logistics by an estimated $0.15-0.25 per SKU, preserving margins across cannabis and beverage lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18-22% of COGS: logistics\u003c\/li\u003e\n\u003cli\u003e$120m FY2024 shipping\/warehousing\u003c\/li\u003e\n\u003cli yoy cost increase\u003e\n\u003c\/li\u003e\n\u003cli\u003e$0.15-0.25 saved per SKU via routing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray 2024 costs: CAD 0.20-0.90\/g cultivation, US$1.945B SG\u0026amp;A+R\u0026amp;D, high logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptilray brands cost structure is driven by cultivation depending on product scale discounts if\u003e10,000 kg\/year), SG\u0026amp;A including marketing (US$525m) and compliance (US$220m), R\u0026amp;D\/product development (~US$1.2B), and logistics (~18-22% of COGS, $120m shipping\/warehousing).\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCultivation\/Processing\u003c\/td\u003e\n\u003ctd\u003eCAD 0.20-0.90\/g\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing (SG\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003eUS$525m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance (SG\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003eUS$220m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/Product Dev\u003c\/td\u003e\n\u003ctd\u003e~US$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e18-22% COGS, $120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ptilray\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult-Use Cannabis Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdult-use cannabis sales generate revenue from flower, pre-rolls, vapes, and edibles sold into recreational markets; this high-volume segment accounted for roughly 55%-60% of Tilray Brands' Canadian cannabis revenue in FY2024, and remained the primary driver into late 2025 as provincial demand and seasonal trends caused monthly sales to swing ±8%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Medical Cannabis Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands earns revenue by selling medical-grade cannabis to patients and pharmacies in markets like Germany and Australia; medical sales contributed about 18% of Tilray Brands' global net revenue in FY2024, with EU medical exports rising 22% year-over-year to $120 million in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeverage Alcohol Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBeverage alcohol sales cover craft beers, spirits, and non-alcoholic drinks sold via retail and hospitality, offering a steadier, diversified revenue base less tied to cannabis rules; after the 2020-2022 acquisitions (Anheuser-Busch JV stake and 2022 Craft Brew asset deals) beverage alcohol accounted for about 35% of Tilray Brands' FY2024 net revenue-roughly $460 million of $1.32 billion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWellness and Hemp Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cprevenue is driven by hemp-based foods supplements and topicals sold via grocery chains e-commerce targeting health-conscious consumers delivering steady cash flow in tilray brands reported approximately us million hemp cbd product revenue across adult-use wellness channels.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eProducts: foods, supplements, topicals\u003c\/li\u003e\n\u003cli\u003eChannels: grocery + e-commerce\u003c\/li\u003e\n\u003cli\u003e2024 hemp CBD revenue: ~US$120M\u003c\/li\u003e\n\u003cli\u003eCustomer base: broader, health-focused demographics\u003c\/li\u003e\n\u003cli\u003eRole: consistent, recurring revenue stream\u003c\/li\u003e\n\n\u003c\/prevenue\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Bulk Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTilray Brands sells bulk cannabis and hemp extracts to other licensed producers, helping clear excess inventory and boost cultivation throughput; in FY2024 wholesale contributed roughly 6-8% of consolidated net revenue, per company filings.\u003c\/p\u003e\n\u003cp\u003eThough margins are lower than finished goods, bulk sales moved millions of grams in 2024 and provided a steady outlet during harvest peaks, smoothing production utilization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 wholesale ≈ 6-8% revenue\u003c\/li\u003e\n\u003cli\u003eMoves millions of grams annually\u003c\/li\u003e\n\u003cli\u003eLower margin, higher volume\u003c\/li\u003e\n\u003cli\u003eImproves facility utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray FY24: Adult-Use Leads (~55-60%), Beverage $460M, Medical $120M EU Exports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray's FY2024 revenue mix: adult-use cannabis ~55-60% (primary driver), medical cannabis ~18% (EU medical exports $120M, +22% YoY), beverage alcohol ~35% (~$460M of $1.32B), hemp CBD ~$120M, wholesale 6-8% (millions of grams moved).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eShare\/Value FY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult-use cannabis\u003c\/td\u003e\n\u003ctd\u003e55-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical cannabis\u003c\/td\u003e\n\u003ctd\u003e~18% (EU exports $120M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeverage alcohol\u003c\/td\u003e\n\u003ctd\u003e~35% ($460M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemp CBD\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\u003c\/td\u003e\n\u003ctd\u003e6-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"VRIO Analysis","offers":[{"title":"Default Title","offer_id":57515405640012,"sku":"tilray-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1056\/0356\/3852\/files\/tilray-canvas-business-model.webp?v=1778643396","url":"https:\/\/vrio-analysis.com\/products\/tilray-business-model-canvas","provider":"VRIO Analysis","version":"1.0","type":"link"}